Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese
adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma.
LBH589 is administered orally once a day for three days per week.